These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 19956876)
1. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Kruck S; Bedke J; Hennenlotter J; Ohneseit PA; Kuehs U; Senger E; Sievert KD; Stenzl A Oncol Rep; 2010 Jan; 23(1):159-63. PubMed ID: 19956876 [TBL] [Abstract][Full Text] [Related]
2. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269 [TBL] [Abstract][Full Text] [Related]
3. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Merseburger AS; Hennenlotter J; Simon P; Kruck S; Koch E; Horstmann M; Kuehs U; Küfer R; Stenzl A; Kuczyk MA Anticancer Res; 2005; 25(3B):1901-7. PubMed ID: 16158924 [TBL] [Abstract][Full Text] [Related]
6. Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Zigeuner R; Droschl N; Tauber V; Rehak P; Langner C Urology; 2006 Sep; 68(3):518-22. PubMed ID: 16979727 [TBL] [Abstract][Full Text] [Related]
7. Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues. Perego RA; Bianchi C; Corizzato M; Eroini B; Torsello B; Valsecchi C; Di Fonzo A; Cordani N; Favini P; Ferrero S; Pitto M; Sarto C; Magni F; Rocco F; Mocarelli P J Proteome Res; 2005; 4(5):1503-10. PubMed ID: 16212400 [TBL] [Abstract][Full Text] [Related]
8. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Shida T; Kishimoto T; Furuya M; Nikaido T; Koda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Tanizawa T; Nakatani Y; Miyazaki M Cancer Chemother Pharmacol; 2010 Apr; 65(5):889-93. PubMed ID: 19657638 [TBL] [Abstract][Full Text] [Related]
9. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872 [TBL] [Abstract][Full Text] [Related]
10. Tissue expression and plasma levels of adrenomedullin in renal cancer patients. Michelsen J; Thiesson H; Walter S; Ottosen PD; Skøtt O; Jensen BL Clin Sci (Lond); 2006 Jul; 111(1):61-70. PubMed ID: 16515534 [TBL] [Abstract][Full Text] [Related]
11. Expression of progranulin and the epithelin/granulin precursor acrogranin correlates with neoplastic state in renal epithelium. Donald CD; Laddu A; Chandham P; Lim SD; Cohen C; Amin M; Gerton GL; Marshall FF; Petros JA Anticancer Res; 2001; 21(6A):3739-42. PubMed ID: 11911241 [TBL] [Abstract][Full Text] [Related]
12. [Detection of Skp2 and p27kip1 expression in human renal cell carcinoma using tissue chip technique]. Yao C; Zheng SB; Wu P; Zhang HJ; Jiang YD; Chen T; Qi H; Zhao GZ; Zhao JF Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):642-5. PubMed ID: 18495610 [TBL] [Abstract][Full Text] [Related]
13. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685 [TBL] [Abstract][Full Text] [Related]
14. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Meyer HA; Tölle A; Jung M; Fritzsche FR; Haendler B; Kristiansen I; Gaspert A; Johannsen M; Jung K; Kristiansen G Eur Urol; 2009 Mar; 55(3):669-78. PubMed ID: 18450365 [TBL] [Abstract][Full Text] [Related]
15. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Miyata Y; Kanetake H; Kanda S Clin Cancer Res; 2006 Aug; 12(16):4876-81. PubMed ID: 16914575 [TBL] [Abstract][Full Text] [Related]
16. Activation of the mTOR signaling pathway in renal clear cell carcinoma. Robb VA; Karbowniczek M; Klein-Szanto AJ; Henske EP J Urol; 2007 Jan; 177(1):346-52. PubMed ID: 17162089 [TBL] [Abstract][Full Text] [Related]
17. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268 [TBL] [Abstract][Full Text] [Related]